Multiple Sclerosis Patients Show Preserved COVID-19 Vaccine Responses Despite Disease-Modifying Therapies
Key Insights
Multiple sclerosis (search) patients treated with fingolimod demonstrated significantly reduced Th1 cytokine responses (IFN-γ (search), IL-2, TNF-α (search)) to COVID-19 (search) vaccines compared to healthy controls, with a 6-fold decrease in IFN-γ and 3-fold reduction in IL-2 production.
Despite impaired cellular immune responses, antibody-mediated protection remained the primary defense against breakthrough infections, with patients mounting antibody responses showing a 70% reduction in breakthrough infection risk.
Natalizumab-treated patients maintained robust humoral and cellular vaccine responses comparable to healthy controls, while also showing increased memory B cell populations and preserved long-term immunity up to 6 months post-vaccination.
Patients with multiple sclerosis (search) (MS) receiving disease-modifying therapies (DMTs) face unique challenges in mounting effective immune responses to COVID-19 (search) vaccines. Two comprehensive studies now provide detailed insights into how different MS treatments affect vaccine-induced immunity, revealing both concerning vulnerabilities and reassuring preservation of protective responses.
Fingolimod Significantly Impairs Cellular Immune Response
A prospective Italian study involving 31 MS patients and 27 healthcare workers examined the cellular immune response following the third dose of COVID-19 (search) mRNA vaccines. The research revealed striking differences in how various DMTs affect vaccine-induced immunity.
Patients treated with fingolimod, a sphingosine-1 phosphate receptor (search) modulator, showed the most pronounced immune impairment. These patients exhibited a 6-fold reduction in interferon-gamma (IFN-γ (search)) production and a 3-fold decrease in interleukin-2 (IL-2) levels compared to healthy controls when exposed to SARS-CoV-2 (search) spike peptides.
"The magnitude of the Th1 response to the Wuhan spike peptides was significantly lower than that observed in healthcare workers, with IFN-γ (search) and TNF-α (search) levels reduced by six-fold, and IL-2 levels decreased by approximately three-fold," the researchers reported.
The study also evaluated responses to the Delta variant, finding that fingolimod-treated patients showed markedly reduced responses across all measured cytokines compared to other DMT groups. Most concerning, there was essentially no response to Delta spike peptides in fingolimod-treated patients, with only minimal cytokine production detected.
Antibody Response Remains Key Protective Factor
Despite the impaired cellular responses, the study identified antibody production as the critical protective factor against breakthrough infections. Among the 31 MS patients followed, 12 (38.7%) experienced breakthrough infections, with the highest rates occurring in patients treated with ocrelizumab (50% of breakthrough cases) and fingolimod (33.3%).
Importantly, patients who mounted an antibody response showed significant protection, with an estimated 70% reduction in breakthrough infection risk. This finding underscores the continued importance of humoral immunity even when cellular responses are compromised.
The research also revealed demographic factors influencing infection risk. Male patients exhibited a 4-fold increased risk of breakthrough infections compared to females, and those with primary progressive MS showed higher infection rates than patients with relapsing-remitting disease.
Natalizumab Preserves Robust Vaccine Responses
A separate longitudinal study from NYU examined 28 MS patients treated with either natalizumab or fumarates, providing encouraging results for natalizumab-treated patients. This research followed patients for up to 6 months after initial vaccination and included analysis of booster responses.
Natalizumab-treated patients demonstrated anti-spike IgG responses comparable to healthy controls throughout the study period. The treatment was associated with increased absolute lymphocyte counts, primarily due to elevated B cell numbers in circulation.
"Anti-Spike IgG levels declined significantly between the 4-week and 8-12-week post-vaccine time point and between the 8-12-week post-vaccine time point and the 5-6-month post-vaccine time point but increased following booster," the researchers noted.
The study revealed that natalizumab treatment led to significant increases in memory B cell populations, particularly classical memory B cells and switched memory B cells. Despite these phenotypic changes, the robust humoral response was maintained.
Distinct Immunological Profiles Emerge
The NYU study also uncovered important differences in T cell responses between treatment groups. Fumarate-treated patients showed a shift toward an anti-inflammatory immune profile, with increased CD4/CD8 ratios and decreased Th1/Th2 ratios compared to natalizumab-treated patients and healthy controls.
In terms of antigen-specific responses, both natalizumab and fumarate-treated patients maintained robust T cell responses to SARS-CoV-2 (search) spike proteins. ELISpot assays measuring IFN-γ (search) and IL-2 secretion showed sustained responses up to 6 months post-vaccination in both treatment groups.
Notably, natalizumab-treated patients showed a unique pattern in their booster response, with a significant increase in Th2 cells among antigen-specific CD4+ T cells. This represented a shift from the typically Th1-dominant response, though effector memory responses remained intact.
Clinical Implications for MS Care
These findings have important implications for MS patient management during ongoing COVID-19 (search) vaccination campaigns. The research suggests that while fingolimod treatment significantly impairs cellular immune responses, the preservation of antibody responses in most patients provides meaningful protection.
For natalizumab-treated patients, the results are particularly reassuring, showing preserved vaccine responses despite the drug's effects on lymphocyte trafficking. The increased memory B cell populations may actually enhance long-term immune memory.
The studies also highlight the importance of individualized risk assessment. Male patients and those with primary progressive MS may benefit from additional protective measures, while the timing of booster doses should consider the specific DMT being used.
Broader Understanding of DMT Mechanisms
Beyond their immediate clinical relevance, these studies provide valuable insights into how different MS therapies affect immune system function. The research demonstrates that fingolimod's mechanism of sequestering lymphocytes in lymph nodes significantly impacts the magnitude of vaccine responses, while natalizumab's effects on lymphocyte trafficking may actually enhance certain aspects of immune memory.
The identification of IL-2 as a valuable biomarker for assessing both cellular and humoral responses adds to the toolkit for monitoring vaccine effectiveness in immunocompromised patients. The correlation between IL-2 levels and neutralizing antibody titers suggests this cytokine could serve as a useful surrogate marker for vaccine response assessment.
These comprehensive studies provide MS patients and their healthcare providers with crucial data for making informed decisions about vaccination strategies and ongoing protective measures during the COVID-19 (search) pandemic.